• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由短暂风险因素引发的首次症状性静脉血栓栓塞发作后的复发风险:一项系统综述

Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review.

作者信息

Iorio Alfonso, Kearon Clive, Filippucci Esmeralda, Marcucci Maura, Macura Ana, Pengo Vittorio, Siragusa Sergio, Palareti Gualtiero

机构信息

Department of Internal Medicine, University of Perugia, Italy.

出版信息

Arch Intern Med. 2010 Oct 25;170(19):1710-6. doi: 10.1001/archinternmed.2010.367.

DOI:10.1001/archinternmed.2010.367
PMID:20975016
Abstract

BACKGROUND

We aimed to determine the risk of recurrence for symptomatic venous thromboembolism (VTE) provoked by different transient risk factors.

DATA SOURCES

MEDLINE, EMBASE, and Cochrane Collaboration Registry of Randomized Trials databases were searched.

STUDY SELECTION

Prospective cohort studies and randomized trials of patients with a first episode of symptomatic VTE provoked by a transient risk factor and treated for at least 3 months were identified.

DATA EXTRACTION

Number of patients and recurrent VTE during the 0- to 12-month and 0- to 24-month intervals after stopping therapy, study design, and provoking risk factor characteristics were extracted.

DATA SYNTHESIS

Annualized recurrence rates were calculated and pooled across studies. At 24 months, the rate of recurrence was 3.3% per patient-year (11 studies, 2268 patients) for all patients with a transient risk factor, 0.7% per patient-year (3 studies, 248 patients) in the subgroup with a surgical factor, and 4.2% per patient-year (3 studies, 509 patients) in the subgroup with a nonsurgical factor. In the same studies, the rate of recurrence after unprovoked VTE was 7.4% per patient-year. The rate ratio for a nonsurgical compared with a surgical factor was 3.0 and for unprovoked thrombosis compared with a nonsurgical factor was 1.8 at 24 months.

CONCLUSIONS

The risk of recurrence is low if VTE is provoked by surgery, intermediate if provoked by a nonsurgical risk factor, and high if unprovoked. These risks affect whether patients with VTE should undergo short-term vs indefinite treatment.

摘要

背景

我们旨在确定由不同短暂危险因素引发的有症状静脉血栓栓塞症(VTE)的复发风险。

数据来源

检索了MEDLINE、EMBASE和Cochrane随机试验协作注册数据库。

研究选择

确定了对由短暂危险因素引发首次有症状VTE且接受至少3个月治疗的患者进行的前瞻性队列研究和随机试验。

数据提取

提取了停药后0至12个月和0至24个月期间的患者数量和复发性VTE、研究设计以及引发危险因素特征。

数据综合

计算年化复发率并在各项研究中进行汇总。在24个月时,所有有短暂危险因素患者的复发率为每年3.3%(11项研究,2268例患者),手术因素亚组为每年0.7%(3项研究,248例患者),非手术因素亚组为每年4.2%(3项研究,509例患者)。在同一组研究中,无诱因VTE后的复发率为每年7.4%。24个月时,非手术因素与手术因素的复发率比值为3.0,无诱因血栓形成与非手术因素的复发率比值为1.8。

结论

手术引发VTE时复发风险低,非手术危险因素引发时复发风险中等,无诱因时复发风险高。这些风险影响VTE患者应接受短期还是长期治疗。

相似文献

1
Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review.由短暂风险因素引发的首次症状性静脉血栓栓塞发作后的复发风险:一项系统综述
Arch Intern Med. 2010 Oct 25;170(19):1710-6. doi: 10.1001/archinternmed.2010.367.
2
Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.不明原因静脉血栓栓塞症(VTE)患者中,检测癌症对癌症或静脉血栓栓塞症(VTE)相关死亡率和发病率的影响。
Cochrane Database Syst Rev. 2021 Oct 1;10(10):CD010837. doi: 10.1002/14651858.CD010837.pub5.
3
Prognosis of adults and children following a first unprovoked seizure.首次无诱因发作后成人和儿童的预后。
Cochrane Database Syst Rev. 2023 Jan 23;1(1):CD013847. doi: 10.1002/14651858.CD013847.pub2.
4
Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation.首次特发性静脉血栓栓塞症治疗后静脉血栓栓塞症复发风险的预测:系统评价、预后模型与临床决策规则以及经济学评估
Health Technol Assess. 2016 Feb;20(12):i-xxxiii, 1-190. doi: 10.3310/hta20120.
5
Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.对无诱因静脉血栓栓塞症(VTE)患者进行癌症检测对癌症及VTE相关死亡率和发病率的影响。
Cochrane Database Syst Rev. 2017 Aug 23;8(8):CD010837. doi: 10.1002/14651858.CD010837.pub3.
6
Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.对有静脉血栓栓塞风险的住院患者实施血栓预防的干预措施。
Cochrane Database Syst Rev. 2018 Apr 24;4(4):CD008201. doi: 10.1002/14651858.CD008201.pub3.
7
Antiplatelet agents for the treatment of deep venous thrombosis.抗血小板药物治疗深静脉血栓形成。
Cochrane Database Syst Rev. 2022 Jul 25;7(7):CD012369. doi: 10.1002/14651858.CD012369.pub2.
8
Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.预防带隧道式中心静脉导管的儿科癌症患者发生静脉血栓栓塞事件的全身治疗。
Cochrane Database Syst Rev. 2013 Sep 11(9):CD009160. doi: 10.1002/14651858.CD009160.pub2.
9
Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.皮下注射普通肝素用于静脉血栓栓塞症的初始治疗。
Cochrane Database Syst Rev. 2017 Feb 14;2(2):CD006771. doi: 10.1002/14651858.CD006771.pub3.
10
Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism.系统评价:D-二聚体用于预测非诱因性静脉血栓栓塞症抗凝治疗停药后的疾病复发
Ann Intern Med. 2008 Oct 7;149(7):481-90, W94. doi: 10.7326/0003-4819-149-7-200810070-00008.

引用本文的文献

1
Extended reduced versus full-dose treatment with factor Xa inhibitors in patients with venous thromboembolism: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.静脉血栓栓塞症患者中,延长减量与全剂量使用Xa因子抑制剂治疗的比较:一项采用GRADE评估的随机对照试验系统评价与荟萃分析
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 22. doi: 10.1007/s00210-025-04388-1.
2
Short and long-term outcomes of COVID-19-associated venous thromboembolism: a propensity score-matched cohort study.新型冠状病毒肺炎相关静脉血栓栓塞症的短期和长期预后:一项倾向评分匹配队列研究
Intern Emerg Med. 2025 Jul 3. doi: 10.1007/s11739-025-04042-x.
3
COVID-19 and Recurrent Venous Thromboembolism (CORE-VTE).
2019冠状病毒病与复发性静脉血栓栓塞症(CORE-VTE)。
Can J Hosp Pharm. 2025 Jul 9;78(3):e3702. doi: 10.4212/cjhp.3702. eCollection 2025.
4
A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya.利伐沙班与华法林用于肯尼亚西部静脉血栓栓塞管理的成本效益分析
Clin Drug Investig. 2025 Jun 28. doi: 10.1007/s40261-025-01454-7.
5
Duration of primary/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis.预防复发性静脉血栓栓塞的初级/二级治疗持续时间:一项系统评价和荟萃分析。
Blood Adv. 2025 Apr 8;9(7):1742-1761. doi: 10.1182/bloodadvances.2024015371.
6
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review.新型抗糖尿病药物与静脉血栓栓塞风险:文献综述
Semin Thromb Hemost. 2025 Mar 28. doi: 10.1055/a-2546-0353.
7
A Saudi Heart Association Position Statement on the use of DOACs in Patients With Arterial and Venous Thrombosis.沙特心脏协会关于在动脉和静脉血栓形成患者中使用直接口服抗凝剂的立场声明。
J Saudi Heart Assoc. 2025 Mar 9;37(2):2. doi: 10.37616/2212-5043.1423. eCollection 2025.
8
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing.激素相关性血栓形成:抗凝持续时间、复发风险及高凝状态检测的作用
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):664-671. doi: 10.1182/hematology.2024000593.
9
External validation of the Leiden Thrombosis Recurrence Risk Prediction models (L-TRRiP) for the prediction of recurrence after a first venous thrombosis in the Heart and Vascular Health study.在心脏与血管健康研究中,对莱顿血栓形成复发风险预测模型(L-TRRiP)进行外部验证,以预测首次静脉血栓形成后的复发情况。
Res Pract Thromb Haemost. 2024 Oct 29;8(8):102610. doi: 10.1016/j.rpth.2024.102610. eCollection 2024 Nov.
10
Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology - 2024.巴西心脏病学会2024年围手术期心血管评估指南。
Arq Bras Cardiol. 2024 Oct 21;121(9):e20240590. doi: 10.36660/abc.20240590.